Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The regimen began with an initial dose of 0.5 mg once weekly during the second month
Gastroenterology 162 (5), 13961408
This resulted in an indication for cardiovascular risk reduction in the drugs US FDA label
It may also be considered for patients who have plateaued on semaglutide or are continuing treatment from another provider
If you have established cardiovascular disease or high risk, the SELECT trial data suggests staying on semaglutide provides ongoing protection
10.1016/j.jchromb.2007.03.010 207 YinH.ZhouY.WenC.ZhouC.ZhangW.HuX.et al (2014)
US$ 28.04
US$ 24.10
US$ 27.32
US$ 26.18
